Company: CORT
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0001628280-25-048841
Chunk: 106

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 2
Chunk 106
---
 of treatment with relacorilant plus nab-paclitaxel.

We will initiate, by early next year, a Phase 2 trial in 50 patients with pancreatic cancer, who have not received prior therapy for metastatic disease, to evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel and gemcitabine.

Our collaborators at the Paris-based academic research cooperative ARCAGY-GINECO will initiate, by early next year, a Phase 2 trial in 50 patients with cervical cancer, who have received one or two prior lines of therapy, to evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel.

The EC has designated relacorilant as an orphan drug for the treatment of ovarian and pancreatic cancers.

Nenocorilant in Combination with Immunotherapy. Immunotherapy harnesses the body’s immune system to identify and destroy cancer cells. We are testing the potential of our proprietary, selective cortisol modulator, nenocorilant to treat cancer by reducing cortisol-activated immune suppression and thereby help the patient’s immune system reduce or eradicate tumors while they receive immunotherapy. We will initiate, by early next year, a Phase 1b dose finding trial in 30 patients with solid tumors to evaluate the efficacy and safety of treatment with nenocorilant plus nivolumab (a PD-1 checkpoint inhibitor). 

Relacorilant in Combination with Androgen Deprivation Therapy. Androgen deprivation is the standard treatment for prostate cancer because androgens stimulate prostate tumor growth. Prostate cancer tumors eventually escape androgen deprivation therapy; one of the prime reasons is that these tumors begin to be stimulated by cortisol’s activity. Combining a cortisol modulator with an androgen modulator may block this escape route. Our collaborators at the University of Chicago have initiated a randomized, placebo-controlled Phase 2 trial of relacorilant plus enzalutamide in patients with prostate cancer, 

21

pre-prostatectomy. Patents we have licensed from the University of Chicago cover the use of relacorilant combined with anticancer agents, including enzalutamide, to treat patients with this disease.

Amyotrophic Lateral Sclerosis (“ALS”)

ALS, also known as Lou Gehrig’s disease, is a devastating neuromuscular illness. Our selective cortisol modulator dazucorilant improved motor performance and reduced neuroinflammation and muscular at